Abbott initiates pivotal trial for Cephea™ device, an innovative treatment for mitral heart valve disease

CROWN-MV trial will evaluate the safety and effectiveness of investigational Cephea mitral valve replacement device Abbott's Cephea is designed to provide a new, minimally invasive option for treating mitral valve disease, the most common type of heart valve ailment 30-day early feasibility study results for Cephea will be presented at TCT 2026 ABBOTT PARK, Ill., Oct. 29, 2026 /PRNewswire/ -- Abbott (NYSE: ABT), the global healthcare leader, announced today it has initiated the CROWN-MV pivotal trial evaluating the safety and effectiveness of its investigational Cephea™ Mitral Valve System in treating people with symptomatic mitral valve disease who are not candidates for surgery and transcatheter repair.

PRNewsWire • 13 hours ago

Best Dividend Aristocrats For November 2026

Dividend Aristocrats underperformed SPY in September but rebounded sharply in October, narrowing the YTD gap. NOBL and the average Aristocrat have YTD returns of 13.13% and 13.35%, trailing SPY's 14.15%. Dividend growth among Aristocrats accelerated, with the 2026 average increase now at 4.55%, bolstered by recent double-digit hikes.

Seeking Alpha • 19 hours ago

U.S. politician makes super suspicious Big Tech stock trades

Republican Rep. Pete Sessions of Texas has disclosed substantial stock sales involving major technology companies.

Finbold • Oct 28, 2026

Is Most-Watched Stock Abbott Laboratories (ABT) Worth Betting on Now?

Abbott (ABT) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

Zacks Investment Research • Oct 27, 2026

Is Abbott (ABT) a Buy as Wall Street Analysts Look Optimistic?

Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter?

Zacks Investment Research • Oct 27, 2026

Medtronic Has Raised Its Dividend for 49 Years. These 2 Rivals Have Even Longer Streaks

Medtronic's 49-year dividend streak sounds impressive until you meet the two medical device rivals that have been raising payouts even longer, and the differences in yield, valuation, and balance sheet strength could reshape how you think about income investing in

24/7 Wall Street • Oct 27, 2026

Abbott: Demand Headwinds And Litigation Risks Priced-In - Spin-Off Tailwinds Ahead

FQ4'26 noise from EP/CGM demand headwinds has contributed to Abbott's lowered FY2026 guidance and range-bound stock price action afterwards. Nutrition spin-off may unlock MedTech/Diagnostic/Pharmaceutical's growth, improve margins, and provide investors with new S&P 500-eligible stock. ABT trades at a P/E of 18.79x, below its 5Y mean/MedTech sector, offering a compelling entry point for double-digit upside potential.

Seeking Alpha • Oct 27, 2026

This Dividend King Just Announced Great News for Investors

Abbott Laboratories' third-quarter results were somewhat mixed, with the company's nutrition business still dragging down sales growth. The healthcare leader announced that it would spin off its nutrition segment into a standalone company, which could help boost revenue growth.

The Motley Fool • Oct 26, 2026

Abbott launches whole-genome sequencing Oncodetect® molecular residual disease (MRD) test to detect traces of cancer during and after treatment

Powered by whole-genome sequencing and MAESTRO * technology, the next-generation Oncodetect test takes a distinct approach to MRD, tracking up to 5,000 patient-specific variants with a limit of detection below one part per million under high-end inputs 1, 2, 3 The next-generation Oncodetect test builds on more than 20 years of trusted leadership in using genomic information to personalize cancer care  Modeling estimates more than 3 million U.S. patients with solid tumors could potentially benefit from MRD testing † ABBOTT PARK, Ill., Oct. 26, 2026 /PRNewswire/ -- For many people with cancer, completing treatment can bring a new uncertainty: Is my cancer really gone?

PRNewsWire • Oct 26, 2026

Abbott Laboratories: A New Growth Story Takes Shape

Abbott Laboratories remains a Buy, driven by robust device and diagnostics growth and the strategic spin-off of its Nutrition business. Devices and diagnostics now comprise 70% of revenue, with Medical Devices up 7.8% and Diagnostics accelerating post-Exact Sciences acquisition. Spinning off Nutrition is expected to boost ABT's growth rate by 50–100 bps, expand gross margin by 200 bps, and improve operating margin by 100 bps.

Seeking Alpha • Oct 26, 2026